Estrogen Therapy in Systemic Lupus Erythematosus

Treatments in Endocrinology

Volumn 3, Issue 1, 2004, Pages 19-26

  Askanase, Anca D ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GONADORELIN; GONADOTROPIN DERIVATIVE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE;

ADULT; BIRTH CONTROL; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE EXACERBATION; ESTROGEN THERAPY; ETHNIC GROUP; FERTILITY; FOLLOW UP; GENDER; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION PROCESS;

CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; REPRODUCTIVE TECHNIQUES, ASSISTED; THROMBOSIS; WOMEN'S HEALTH;

EID: 0942266140     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403010-00003     Document Type: Review

References (76)

1. Masi AT, Kaslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978; 21: 480-4
2. Lahita RG, Bradlow HL. Hormone metabolism in patients with Klinefelter's disease and SLE. J Rheumatol 1987; 14: 154-7
3. Inman RD. Immunologic sex differences and the female preponderance in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 849-52
4. Lahita RG, Bradlow HL, Fishman J, et al. Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum 1982; 25: 843-6
5. Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241-8
6. Yocum MW, Grossman J, Waterhouse C, et al. Monozygotic twins discordant for systemic lupus erythematosus: comparison of immune response, autoantibodies, viral antibody titers, gamma globulin, and light chain metabolism. Arthritis Rheum 1975; 18: 193-9
7. Molero L, Garcia-Duran M, Diaz-Recasens J, et al. Expression of estrogen receptor subtypes and neuronal nitric oxide synthase in neutrophils from women and men: regulation by estrogen. Cardiovasc Res 2002; 56 (1): 4-7
8. Murad F, Kuret J. Estrogens and progestins. In: Gilman AG. Rall TW, Nies AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1998: 1411-57
9. Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 1987; 18: 237-83
10. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993; 259: 633-8
11. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-23
12. Mintz G, Gutierrez G, Deleze M, et al. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984; 30: 29-38
13. Roubinian J, Talal N, Siiteri PK, et al. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979; 11: 1162-9
14. Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994; 170: 1523-7
15. Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33-8
16. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20: 427-33
17. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993; 32: 227-30
18. Tinkle M, Reifsnider E, Ransom SP. Why women quit using Depo-Provera? AWHONN Lifelines 2001; 5 (6): 36-41
19. Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40: 804-8
20. Todd GR, McAteer EJ, Jack CM, et al. Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill. Ann Rheum Dis 1985; 44: 266-7
21. Garovich M, Aguldo C, Pisko E. Oral contraceptives and systemic lupus erythematosus. Arth Rheum 1980; 23: 1396-8
22. Travers RL, Hughes GRV. Oral contraceptive therapy and systemic lupus erythematosus. J Rheum 1978; 5: 448-51
23. Chapel TA, Burns RE. Oral contraceptives and exacerbations of lupus erythematosus. Am J Obstet Gynecol 1971; 110: 366-9
24. Hadida M, Sayag J. Lupus erythemateux subaigu apparu apres une cure de Norlutin chez une malade atteinte de lupus erythematreux chronique. Soc Franc Derm Syph Bull 1968; 74: 616-21
25. Pimstone BL. Systemic lupus erythematosus exacerbated by oral contraceptives. S Afr J Obstet Gynaec 1966; 4: 62-3
26. Furukawa F, Tachibana T, Imamura S, et al. Oral contraceptive-induced lupus erythematosus in a Japanese woman. J Derm 1991; 18: 56-8
27. Miller MH. Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report. Ann Rheum Dis 1987; 46: 159-61
28. Buyon JP, Kalunian KC, Skovron ML, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol 1995; 1: 205-12
29. Tarzy BJ, Garcia CR, Wallach EE, et al. Rheumatic disease, abnormal serology and oral contraceptives. Lancet 1972; II (7776): 501-3
30. Dubois EL, Strain L, Ehn M, et al. LE cells after oral contraceptives. Lancet 1968; 11 (7569): 679
31. McKenna CH, Wieman KC, Shulman LE. Oral contraceptives, rheumatic disease and autoantibodies. Arthritis Rheum 1969; 12: 313
32. Kay DR, Bole GG, Ledger WJ. Antinuclear antibodies, rheumatoid factor and C-reactive protein in serum of normal women using oral contraceptives. Arthritis Rheum 1971; 14: 239-48
33. Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiological studies. Obstet Gynecol 1985; 152: 729-98
34. Asherson RA, Harris EN, Hughes GRV. Complications of oral contraceptives and antiphospholipid antibodies [letter]. Arthritis Rheum 1988; 31: 575-6
35. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-8
36. Strolin-Benedetti M, Gutty D, Strolin P. A comparative study of the effect of oral contraceptives and cigarette smoking on platelet adhesiveness. Haemostasis 1976; 5: 14-20
37. Schwartz J, Freeman R, Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995; 35: 314-29
38. Pizzo SV, Lewis JG, Campbell EE, et al. Fibrinolytic response and oral contraceptive associated thromboembolism. Contraception 1981; 23: 181-6
39. Carreras LO, Vermylen JG, 'Lupus' anticoagulant and thrombosis, possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 28-40
40. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation: a review. Obstet Gynecol Surv 1985; 40: 425-36
41. Anonymous. Estrogen dose in oral contraceptives: FDA committee examines safety and utility of 50 mcg estrogen OCs. Contracept Rep 1994; 5: 10-3
42. 2-glycoprotein 1. J Clin Invest 1992; 90: 1100-4
43. Vande Wiele RL, Dyrenfurth I. Gonadotropin-steroid interrelationships. Pharmacol Rev 1973; 25: 189-207
44. Levitz M, Young BK. Estrogens in pregnancy. Vitam Horm 1977; 35: 109-47
45. Buster JE. Estrogen metabolism. In: Sperott C, Simpson JL, editors. Reproductive endocrinology, infertility and genetics. Hagerstown (MD): Harper & Row, 1980: 1
46. Quigley M. Pharmacologically enhanced follicular recruitment for in vitro fertilization. In: Collins R, editor. Ovulation induction. Berlin: Springer-Verlag, 1991: 153-63
47. Ben-Chetrit A, Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum 1994; 37: 1614-7
48. Casoli P, Tumiati B, La Sala G. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 1997; 24: 1639-40
49. Huong DL, Wechsler B, Piette JC, et al. Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 1184-6
50. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000; 43: 550-6
51. Beerendonk CC, van Dop PA, Braat DD, et al. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv 1998; 43: 439-49
52. Isacs JD. Gonadotropin-releasing hormone analogs. In: Cowan BD, Seifer DB, editors. Clinical reproductive medicine. New York: Lippincott-Raven, 1997: 225-9
53. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345: 34-40
54. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-46
55. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 882-90
56. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992; 7: 1063-9
57. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-505
58. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001; 44: 1496-503
59. Sowers MFR, Galuska DA. Epidemiology of bone mass in premenopausal women. Epidemiol Rev 1993; 15: 374-98
60. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13
61. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-52
62. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9
63. Lenfant C. Preliminary trends in the Women's Health Initiative. Bethesda (MD): National Heart, Lung, and Blood Institute Communications Office, 2000 Apr 3
64. Writing group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
65. Castellsague J, Perez Gutthann S, Garcia Rodriguez LA, Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: a review. Drug Saf 1998; 18: 117-23
66. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96
67. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834-9
68. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2000; 288: 872-81
69. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 28: 361-8
70. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-5
71. Rosner S, Ginzler EM, Diamond HS, et al. A multicenter study of outcome in systemic lupus erythematosus: II. Causes of death. Arthritis Rheum 1982; 25: 612-7
72. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981; 70: 775-81
73. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60
74. Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. Effect of hormone replacement (HRT) on disease activity in postmenopausal patients with (SLE): a two-year follow-up clinical trial [abstract]. Arthritis Rheum 2001; 44 Suppl.: S263
75. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45
76. Walsh BW, Kuller LH, Wild RA, et al. Effects of Raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51